Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Trial number:
NCT05425940
Trial phase:
3
Study type:
Immunotherapy, Targeted therapy
Overall status:
Recruiting

Study start date

September, 2022

Scientific title

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Summary

This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed after or are intolerant to standard-of-care (SOC) therapy.

Subjects with histologically or cytologically confirmed adenocarcinoma of the colon or rectum.

Documented RAS status (mutant or wild-type [WT]), by tissue-based analysis.Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.

Has received standard-of-care (SOC) anticancer therapies as prior therapy for metastatic CRC and has radiographically progressed, is refractory or intolerant to these therapies.

Radiographic progression during treatment with or within 3 months following the last dose of the most recent approved SOC chemotherapy regimen.Measurable disease according to RECIST v1.1 as determined by the Investigator. Available archival tumor biopsy material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization. Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy. Age 18 years or older on the day of consent. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Adequate organ and marrow function.

Prior treatment with XL092, regorafenib, trifluridine/tipiracil, or PD-L1/PD-1 targeting immune checkpoint inhibitors (ICIs).Receipt of a small molecule kinase inhibitor (including investigational agents) within 2 weeks before randomization. Receipt of any type of anticancer antibody therapy, systemic chemotherapy, or hormonal anti-cancer therapy within 3 weeks (or bevacizumab within 4 weeks) before randomization. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before randomization. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization. Concomitant anticoagulation with oral anticoagulants and platelet inhibitors. Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms within 10 days before randomization. Pregnant or lactating females. Administration of a live, attenuated vaccine within 30 days before randomization.

Study design

Primary purpose: Treatment, Allocation: Randomized, Intervention model: Parallel Assignment, Masking: None (Open Label),

Conditions

Colorectal Cancer

Other study ID numbers

XL092-303; 2021-003243-21

Choose trial site (18)

Farrer Park
Farrer Park Recruiting